Bridging the gap does not mean adding more work. Adding nutrition with your pesticide application is an effective way to address in-season nutrient demand without concern for crop safety.
Yara offers an easy to use website (www.tankmix.com) and app (TankmixIT) which allows growers to rest assured knowing that the product and pesticides will mix without an issue or loss in time. Confidence is key to foliar nutrition and Yara is here to help.
Foliar nutrition is essential to every crop nutrition plan. Nutritional demand of the crop and nutrient availability from the soil varies throughout the crop year. By including foliar nutrition in their crop plan, growers can feel confident they are being proactive in addressing any concerns that may arise.
A complete nutrition program including foliar nutrition will supply the right nutrients to the crop at the right time, where the crop can take up throughout the growth cycle.
Plant on the left is nutrient deficient. Plant on the right has received optimal nutrition.
Foliar nutrition can help you mitigate crop stress. Foliar phosphate can increase root volume by 1.5 times. By promoting root development you are increasing access to more nutrients and soil moisture.
YaraVita® is the go-to workhorse for foliar nutrition. Yara’s legendary quality gives growers confidence that the product will perform in the field safely and efficiently. All YaraVita foliar products consist of high-quality nutrients to ensure safe application directly to the crops and have been formulated with wetting-agents to promote even spreading across the crop and optimal uptake.
Foliar nutrition is essential to taking the next step in increasing farm profitability through crop nutrition. Yara’s years of research shows that the use of foliar nutrition proactively will give higher farm profitability through increased yield and quality.
In these trials, YaraVita Foliar Products were applied proactively at specific crop stages in wheat and canola.
70% of the trials showed a positive return on investment, and 44% of the trials had a ROI greater than 3:1.